Role of medial smooth muscle cell function in antithrombogenicity of vein grafts.

Abstract

To determine the significance of prostaglandin I2 (PGI2) production by medial smooth muscle cells (SMCs), we assessed PGI2 production from denuded vein grafts and their antithrombogenicity. A total of 30 dogs were divided into two groups: in group I, 14 dogs (27 veins, 188 segments) were used to assay PGI2 production, which was measured as 6-keto-PGF1 alpha. In group II, 16 dogs were used for an implantation study and the thrombus-free surface (TFS) score was calculated 24 h after implantation. Both groups contained the following subgroups: subgroup A, freshly harvested veins; subgroup B, endothelial denuded veins; subgroup C, veins frozen and cryopreserved; subgroup D, veins treated with protease. Values of 6-keto-PGF1 alpha (pg/mg/min) for basal and stimulated states in subgroup I-A through I-D were 58.0 +/- 8.9 and 530.6 +/- 74.7, 26.3 +/- 4.7 and 82.3 +/- 11.4, 17.9 +/- 1.3 and 39.4 +/- 3.3, and 13.3 +/- 1.8 and 32.2 +/- 6.2, respectively. The PGI2 production in subgroup I-A were significantly higher than those in the other three subgroups (p < 0.01 for basal and stimulated), while the production in subgroup I-B was also significantly higher than those in the remaining two (p < 0.05 for basal and stimulated). The TFS scores in subgroup II-A through II-D were 98 +/- 2%, 90 +/- 2%, 38 +/- 5%, and 15 +/- 7%, respectively, showing significantly superior antithrombogenicity in subgroup II-B, as well as in II-A, when compared with the remaining two (p = 0.014). The amount of PGI2 generated by the medial SMCs may be sufficient for maintaining the antithrombogenicity of the endothelial denuded AVGs.